In a study including 500 patients receiving the BTK inhibitor ibrutinib, 71% of patients who were normotensive at baseline developed new hypertension and 83% of patients with baseline hypertension experienced worsening of hypertension.171 However, another study in patients with chronic lymphocytic leukemia reported an incidence of ibrutinib-induced hypertension of 20% over a median follow-up of 29 months.172 Nonetheless, BTK inhibitors are frequently administered for prolonged periods of time, and this increased tendency to develop hypertension contributes to long-term cardiovascular risk. Here, BTK is linked to B-cell chronic lymphocytic leukemia.